MSC-derived exosomes attenuate hepatic fibrosis in primary sclerosing cholangitis through inhibition of Th17 differentiation

Abstract

Primary sclerosing cholangitis (PSC) is an autoimmune cholangiopathy characterized by chronic inflammation of the biliary epithelium and periductal fibrosis, with no curative treatment available, and liver transplantation is inevitable for end-stage patients. Human placental mesenchymal stem cell (hpMSC)-derived exosomes have demonstrated the ability to prevent fibrosis, inhibit collagen production and possess immunomodulatory properties in autoimmune liver disease. Here, we prepared hpMSC-derived exosomes (Exo^MSC) and further investigated the anti-fibrotic effects and detailed mechanism on PSC based on Mdr2^−/− mice and multicellular organoids established from PSC patients. The results showed that Exo^MSC ameliorated liver fibrosis in Mdr2^−/− mice with significant collagen reduction in the preductal area where Th17 differentiation was inhibited as demonstrated by RNAseq analysis, and the percentage of CD4⁺IL-17A⁺T cells was reduced both in Exo^MSC-treated Mdr2^−/− mice (Mdr2^−/−-Exo) in vivo and Exo^MSC-treated Th17 differentiation progressed in vitro. Furthermore, Exo^MSC improved the hypersecretory phenotype and intercellular interactions in the hepatic Th17 microenvironment by regulating PERK/CHOP signaling as supported by multicellular organoids. Thus, our data demonstrate the anti-fibrosis effect of Exo^MSC in PSC disease by inhibiting Th17 differentiation, and ameliorating the Th17-induced microenvironment, indicating the promising potential therapeutic role of Exo^MSC in liver fibrosis of PSC or Th17-related diseases.

Graphical abstract

Keywords

Mesenchymal stem cell / Exosomes / Primary sclerosing cholangitis / Fibrosis / Organoids / Th17

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This work was supported by grants for National Key Research and Development Program of China (No. 2020YFA0113003 ), Key Research and Development Project of Zhejiang Province (No. 2023C03046), Fundamental Research Funds for the Central Universities (No. 2022ZFJH003), andResearch Project of Jinan Microecological Biomedicine Shandong Laboratory (No. JNL-2022026C, JNL-2023003C).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2024.100889.

References

[1] Sato K, Glaser S, Kennedy L, Liangpunsakul S, Meng F, Francis H, et al. Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets. Expert Opin Ther Targets 2019; 23(6):461-72.

[2] Poch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M, et al. Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+T cells in primary sclerosing cholangitis. J Hepatol 2021; 75(2):414-23.

[3] Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145(3):521-36.

[4] Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol 2017; 67(6):1298-323.

[5] Sato K, Zhang W, Safarikia S, Isidan A, Chen AM, Li P, et al. Organoids and spheroids as models for studying cholestatic liver injury and cholangiocarcinoma. Hepatology 2021; 74(1):491-502.

[6] Hirschfield GM, Gershwin ME. The Immunobiology and pathophysiology of primary biliary cirrhosis. Ann Rev Pathol: Mech Dis 2013;8:303-30.

[7] Nakamoto N, Sasaki N, Aoki R, Miyamoto K, Suda W, Teratani T, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 2019; 4(3):492-503.

[8] Kummen M, Holm K, Anmarkrud JA, Nygard S, Vesterhus M, Hoivik ML, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017; 66(4):611-19.

[9] Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. New Engl J Med 2016; 375(12):1161-70.

[10] Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, et al. Bile-derived organoids from patients with primary sclerosing cholangitis recapitulate their inflammatory immune profile. Hepatology 2019; 70(3):871-82.

[11] Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004; 127(1):261-74.

[12] Fickert P, Fuchsbichler A, Marschall HU, Wagner M, Zollner G, Krause R, et al. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol 2006; 168(2):410-22.

[13] Nishio T, Hu R, Koyama Y, Liang S, Rosenthal SB, Yamamoto G, et al. Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. J Hepatol 2019; 71(3):573-85.

[14] Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 2016; 63(2):512-23.

[15] Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. J Hepatol 2016; 64(3):674-81.

[16] Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127(5):1565-77.

[17] Fickert P, Pollheimer MJ, Beuers U, Lackner C, Hirschfield G, Housset C, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014; 60(6):1290-303.

[18] Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut 2019; 68(12):2228-37.

[19] Brevini T, Tysoe OC, Sampaziotis F. Tissue engineering of the biliary tract and modelling of cholestatic disorders. J Hepatol 2020; 73(4):918-32.

[20] Mischiati C, Ura B, Roncoroni L, Elli L, Cervellati C, Squerzanti M, et al. Changes in protein expression in two cholangiocarcinoma cell lines undergoing formation of multicellular tumor spheroids in vitro. PLoS One 2015; 10(3):e0118906.

[21] Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014; 345(6194):1247125.

[22] Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, et al. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab 2019; 30(2):374-84 e6.

[23] Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 2018; 18(1):335.

[24] Kim M, Mun H, Sung CO, Cho EJ, Jeon HJ, Chun SM, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 2019; 10(1):3991.

[25] Jager M, Blokzijl F, Sasselli V, Boymans S, Janssen R, Besselink N, et al. Measuring mutation accumulation in single human adult stem cells by whole-genome sequencing of organoid cultures. Nat Protoc 2018; 13(1):59-78.

[26] Kimura M, Iguchi T, Iwasawa K, Dunn A, Thompson WL, Yoneyama Y, et al. En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH. Cell 2022; 185(22):4216-32 e16.

[27] Vesterhus M, Holm A, Hov JR, Nygård S, Schrumpf E, Melum E, et al. Novel serum and bile protein markers predic primary sclerosing cholangitis disease severity and prognosis. J Hepatol 2017; 66(6):1214-22.

[28] Zweers SJ, Shiryaev A, Komuta M, Vesterhus M, Hov JR, Perugorria MJ, et al. Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis. Liver Int 2016; 36(9):1370-7.

[29] Strazzabosco M, Fiorotto R, Cadamuro M, Spirli C, Mariotti V, Kaffe E, et al. Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. Biochim Biophys Acta Mol Basis Dis 2018; 1864(4 Pt B): 1374-1379.

[30] Wu N, Meng F, Zhou T, Venter J, Giang TK, Kyritsi K, et al. The secretin/secretin receptor axis modulates ductular reaction and liver fibrosis through changes in transforming growth factor-β1-mediated biliary senescence. Am J Pathol 2018; 188(10):2264-80.

[31] Oo YH, Banz V, Kavanagh D, Liaskou E, Withers DR, Humphreys E, et al. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol 2012; 57(5):1044-51.

[32] Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature 2019; 576(7785):143-8.

[33] Su Y, Lu N, Li Q, Wen H, Zhang XQ, Zhang M. Gut Microbiota and drug-related liver injury: challenges and perspectives. Adv Gut Microbiome Res 2023;2023:5442597.

[34] Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143(3):765-76 e3.

[35] Berardis S, Dwisthi Sattwika P, Najimi M, Sokal EM. Use of mesenchymal stem cells to treat liver fibrosis: current situation and future prospects. World J Gastroenterol 2015; 21(3):742-58.

[36] Ge J, Wang K, Meng QH, Qi ZX, Meng FL, Fan YC. Implication of Th17 and Th1 cells in patients with chronic active hepatitis B J Clin Immunol 2010; 30(1):60-7.

[37] Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, et al. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009; 49(2):646-657.

[38] Sato K, Kennedy L, Liangpunsakul S, Kusumanchi P, Yang Z, Meng F, et al. Intercellular communication between hepatic cells in liver diseases. Int J Mol Sci 2019; 20(9):2180.

[39] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2):209-18.

[40] Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA 2014; 111(32):E3297-305.

[41] Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45(3):429-38.

[42] Wells RG, Schwabe RF. Origin and function of myofibroblasts in the liver. Semin Liver Dis 2015; 35(2):97-106.

[43] Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82(24):8681-5.

[44] Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13(11):1324-32.

[45] Sato K, Marzioni M, Meng F, Francis H, Glaser S, Alpini G. Ductular reaction in liver diseases: pathological mechanisms and translational significances. Hepatology 2019; 69(1):420-30.

[46] Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99(10):3838-43.

[47] Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30(1):42-8.

[48] Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 2005; 35(5):1482-90.

[49] Pianta S, Bonassi Signoroni P, Muradore I, Rodrigues MF, Rossi D, Silini A, et al. Amniotic membrane mesenchymal cells-derived factors skew T cell polarization toward Treg and downregulate Th1 and Th17 cells subsets. Stem Cell Rev Rep 2015; 11(3):394-407.

[50] Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12(5):383-96 Epub 2012/04/26.

[51] Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020; 367(6478):eaau6977.

[52] Psaraki A, Ntari L, Karakostas C, Korrou-Karava D, Roubelakis MG. Extracellular vesicles derived from mesenchymal stem/stromal cells: the regenerative impact in liver diseases. Hepatology 2022; 75(6):1590-603.

[53] Kordelas L, Rebmann V, Ludwig AK, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014; 28(4):970-3.

[54] Lin F, Chen W, Zhou J, Zhu J, Yao Q, Feng B, et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11in acute liver injury. Cell Death Dis 2022; 13(3):271.

[55] Qu Y, Zhang Q, Cai X, Li F, Ma Z, Xu M, et al. Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J Cell Mol Med 2017; 21(10):2491-502.

[56] Lou G, Yang Y, Liu F, Ye B, Chen Z, Zheng M, et al. MiR-122 modification enhances the therapeutic efficacy of adipose tissue-derived mesenchymal stem cells against liver fibrosis. J Cell Mol Med 2017; 21(11):2963-73.

[57] Lou G, Chen Z, Zheng M, Liu Y. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Exp Mol Med 2017; 49(6):e346.

[58] Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 2013; 22(6):845-54.

[59] Chen L, Lu FB, Chen DZ, Wu JL, Hu ED, Xu LM, et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. Mol Immunol 2018;93:38-46.

[60] Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013; 58(3):522-8.

[61] Yang JJ, Liu LP, Tao H, Hu W, Shi P, Deng ZY, et al. MeCP2 silencing of LncRNA H19 controls hepatic stellate cell proliferation by targeting IGF1R Toxicology 2016;359-360:39-46.

[62] Hyun J, Wang S, Kim J, Kim GJ, Jung Y. MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by chorionic plate-derived mesenchymal stem cells Sci Rep 2015;5:14135.

[63] Chen W, Zhu J, Lin F, Xu Y, Feng B, Feng X, et al. Human placenta mesenchymal stem cell-derived exosomes delay H2O2-induced aging in mouse cholangioids. Stem Cell Res Ther 2021; 12(1):201.

[64] Yao Q, Chen W, Yu Y, Gao F, Zhou J, Wu J, et al. Human placental mesenchymal stem cells relieve primary sclerosing cholangitis via upregulation of TGR5 in Mdr2(-/-) Mice and human intrahepatic cholangiocyte organoid models. Research 2023;6:0207.

[65] Niknam B, Baghaei K, Mahmoud Hashemi S, Hatami B, Reza Zali M, Amani D. Human Wharton’s jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis Int Immunopharmacol 2023;119:110294.

[66] Lin Y, Yan M, Bai Z, Xie Y, Ren L, Wei J, et al. Huc-MSC-derived exosomes modified with the targeting peptide of aHSCs for liver fibrosis therapy. J Nanobiotechnology 2022; 20(1):432.

[67] Chen W, Yao Q, Wang R, Fen B, Chen J, Xu Y, et al. Highly efficient methods to culture mouse cholangiocytes and small intestine organoids. Front Microbiol 2022;13:907901.

[68] Stein S, Henze L, Poch T, Carambia A, Krech T, Preti M, et al. IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. J Hepatol 2021; 74(4):919-30.

[69] Chen L, Bai J, Peng D, Gao Y, Cai X, Zhang J, et al. SZB120 exhibits immunomodulatory effects by targeting eIF2α to suppress Th17 cell differentiation. J Immunol 2021; 206(5):953-62.

[70] Marciniak SJ, Garcia-Bonilla L, Hu J, Harding HP, Ron D. Activation-dependent substrate recruitment by the eukaryotic translation initiation factor 2 kinase PERK. J Cell Biol 2006; 172(2):201-9.

[71] Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2013; 73(6):1993-2002.

[72] Liu R, Li X, Huang Z, Zhao D, Ganesh BS, Lai G, et al. C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice. Hepatology 2018; 67(4):1441-57.

[73] Dong C. Genetic controls of Th17 cell differentiation and plasticity. Exp Mol Med 2011; 43(1):1-6.

[74] Mandal A, Kumbhojkar N, Reilly C, Dharamdasani V, Ukidve A, Ingber DE, et al. Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations. Sci Adv 2020; 6(30):eabb6049.

[75] Kakiuchi N, Yoshida K, Uchino M, Kihara T, Akaki K, Inoue Y, et al. Frequent mutations that converge on the NFKBIZ pathway in ulcerative colitis. Nature 2020; 577(7789):260-5.

[76] Kunzmann LK, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, et al. Monocytes as potential mediators of pathogen-induced T-helper 17 differentiation in patients with primary sclerosing cholangitis (PSC). Hepatology 2020; 72(4):1310-26.